Saliva as a testing specimen with or without pooling for SARS-CoV-2 detection by multiplex RT-PCR test

Qing Sun^{1*}, Jonathan Li¹, Hui Ren¹, Larry Pastor¹, Yulia Loginova¹, Roberta Madej¹, Kristopher Taylor², Joseph K. Wong², Zhao Zhang¹, Aiguo Zhang¹, Chuanyi M. Lu^{2*} and Michael Y. Sha^{1*}

¹DiaCarta Inc. 2600 Hilltop Dr. Richmond, CA 94806; ² University of California and VA Healthcare System, San Francisco, CA 94121.

*Correspondence to authors: gsun@diacarta.com; mark.lu@va.gov and msha@diacarta.com

Running title: Saliva for SARS-COV-2 detection

Abstract

Background

Sensitive and high throughput molecular detection assays are essential during the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The vast majority of the SARS-CoV-2 molecular assays use nasopharyngeal swab (NPS) or oropharyngeal swab (OPS) specimens collected from suspected individuals. However, using NPS or OPS as specimens has apparent drawbacks, e.g. the collection procedures for NPS or OPS specimens can be uncomfortable to some people and may cause sneezing and coughing which in turn generate droplets and/or aerosol particles that are of risk to healthcare workers, requiring heavy use of personal protective equipment. There have been recent studies indicating that self-collected saliva specimens can be used for molecular detection of SARS-CoV-2 and provides more comfort and ease of use for the patient. Here we report the performance of QuantiVirus™ SARS-CoV-2 multiplex test using saliva as the testing specimens with or without pooling.

Methods

Development and validation studies were conducted following FDA-EUA and molecular assay validation guidelines. Using SeraCare Accuplex SARS-CoV-2 reference panel, the limit of detection (LOD) and clinical evaluation studies were performed with the QuantiVirus™ SARS-CoV-2 multiplex test. For clinical evaluation, 85 known positive and 90 known negative clinical NPS samples were tested. Additionally, twenty paired NPS and saliva samples collected from recovering COVID-19 patients were tested and the results were further compared to that of the Abbott m2000 SARS-CoV-2 PCR assay. Results of community collected 389 saliva samples for COVID-19 screening by QuantiVirus™ SARS-CoV-2 multiplex test were also obtained and analyzed. Moreover, saliva pooling with 6 and 12 samples together were also evaluated.

Results

The LOD for the QuantiVirus™ SARS-CoV-2 multiplex test was confirmed to be 100-200 copies/mL. The clinical evaluation using contrived saliva samples indicated that the positive percentage agreement (PPA) of the QuantiVirus™ SARS-CoV-2 multiplex test is

100% at 1xLOD, 1.5xLOD and 2.5xLOD. No cross-reactivity was observed for the QuantiVirus™ SARS-CoV-2 multiplex test with common respiratory pathogens. Testing of clinical samples showed a positive percentage agreement (PPA) of 100% (95% CI: 94.6% to 100%) and a negative percentage agreement (NPA) of 98.9% (95% CI: 93.1% to 99.9%). QuantiVirus™ SARS CoV-2 multiplex test had 80% concordance rate and no significant difference ($p=0.13$) in paired saliva and NPS specimens by Wilcoxon matched pairs signed rank test. Positive test rate was 1.79% for 389 saliva specimens collected from the communities for COVID-19 screening. Preliminary data showed that saliva sample pooling up to 6 samples for SARS-CoV-2 detection is feasible (sensitivity 94.8% and specificity 100%).

Conclusion

The studies demonstrated that the QuantiVirus™ SARS-CoV-2 multiplex test has a LOD of 200 copies/mL in contrived saliva samples. The clinical performance of saliva-based testing is comparable to that of NPS-based testing. Pooling of saliva specimens for SARS-CoV-2 detection is feasible. Saliva based and high-throughput QuantiVirus™ SARS-CoV-2 multiplex test offers a highly desirable test during the ongoing COVID-19 pandemic.

Introduction

A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, previously provisionally named 2019 novel coronavirus or 2019-nCoV), has been identified as the cause of respiratory infection including severe pneumonia outbreak that started in Wuhan, China in late 2019¹⁻², and has since become a global pandemic. The disease was named the coronavirus disease of 2019 (COVID-19) by the World Health Organization in February 2020. It has been determined that SARS-CoV-2 can be transmitted from person-to-person (symptomatic or asymptomatic) and is more transmissible than SARS-CoV³⁻⁵.

Nasopharyngeal swab (NPS) and oropharyngeal swab (OPS) samples are widely accepted as specimens for the detection of SARS-CoV-2 since the start of the COVID-19 pandemic. However, the collection procedures for NPS and OPS specimens may cause discomfort and, in some people, sneezing and coughing. The latter in turn can generate droplets or aerosol particles that place healthcare workers collecting these specimens at risk,⁶ requiring heavy use of personal protective equipment (PPE). Poor tolerability of NPS and OPS sampling can result in false-negative tests due to inadequate or poor quality of specimen collection⁷⁻¹⁰. Recent investigations by Wyllie et al¹¹ and Hanson et al¹² suggested that saliva is a viable and even more sensitive alternative to NPS specimens, and could also enable at-home self-administered sample collection for large-scale SARS-CoV-2 molecular testing. Other researchers also reported that SARS-CoV-2 was detected in 91.7% (n=11) of the initial saliva specimens from confirmed COVID-19 patients. All saliva specimens (n=33) collected from patients whose NPS specimens tested negative for COVID-19 also tested negative¹³. It is apparent that detection of SARS CoV-2 in saliva can be used as an alternative, more appealing and cost-effective

procedure for the diagnosis of COVID-19. Indeed, a molecular test using saliva samples was first approved for FDA under EUA on May 8, 2020.¹⁴

The use of saliva specimens might decrease the risk of nosocomial transmission of COVID-19 and is ideal for situations in which NPS or OPS specimen collection may be impractical.¹⁵⁻¹⁸ Collecting saliva is easy and more tolerable to patients, can reduce risk of cross-infection, and can be used in settings where PPE is not readily available. It will also be useful for testing infants and young children in daycare facilities and schools.

The QuantiVirus™ SARS-CoV-2 Multiplex Test is a real-time reverse transcription polymerase chain reaction (RT-qPCR) test that includes the assay controls for the qualitative detection of viral RNA from SARS-CoV-2 in NPS, OPS, saliva or sputum specimens collected from patients who are suspected of COVID-19 infection. Extracted RNA is reverse-transcribed and amplified in a single reaction. In this multiplex qPCR method, the Orf1ab, N, and E genes of the SARS-CoV-2 genome are targeted in the RT-PCR assay (Figure 1A). Primers and TaqMan probes designed for conserved regions of the SARS-CoV-2 virus genome allow specific amplification and detection of the viral RNA from all strains of SARS-CoV-2 from respiratory specimens. The Human RNase P gene is used as an Internal Control (IC) to monitor viral RNA extraction efficiency and assess amplifiable RNA in the samples to be tested. The test is a multiplex RT-PCR assay consisting of one reaction with primers and probes for the viral gene targets (Orf1ab, N and E genes) and IC in one tube, designed to increase assay throughput.

We demonstrate here that saliva sampling is an adequate alternative to NPS and OPS sampling and can be used for COVID-19 testing using the QuantiVirus SARS-CoV-2 multiplex test.

Methods

Study design and ethics

Besides contrived saliva samples, deidentified leftover patient NPS and saliva samples were used in the study. All patient specimens were collected in June-September 2020 and previously tested at UCSF affiliated San Francisco VAMC clinical laboratories and DiaCarta clinical laboratory for clinical diagnostic or screening purpose. Other than qualitative RT-PCR results (positive or negative), only PCR cycle threshold (Ct) values were included in study analysis and no patient clinical chart reviews were performed. This study was approved by the institutional review board (IRB) at UCSF (UCSF IRB #11-05207) as a no-subject contact study with waiver of consent and as exempt under category 4.

Clinical specimens

Clinical samples were collected from patients who had previously been tested positive for SARS-CoV-2. Paired NPS and saliva samples were collected at the same time. The QuantiVirus™ Saliva Collection Kit (DiaCarta, Inc. cat# DC-11-0021) was used for saliva collection, following the kit insert instructions and under the supervision of healthcare providers. Each saliva sample contains 2 mL liquid saliva and 2 mL viral transport media. The NPS and saliva samples are refrigerated and processed for testing within 24 hours after collection.

Sample pooling

Patient saliva and healthy saliva samples were pooled together according to the experiment design for 1:5 (i.e., 1 positive mixed with 5 negatives) and 1:11 (i.e., 1 positive mixed with 11 negatives) pooling. After mixing the samples, the viral RNA was extracted according to the following protocol.

Viral RNA extraction

MGI's automatic RNA/DNA extraction instrument MGISP-960 or Thermo PureLink™ Viral RNA/DNA Mini Kit (Cat. 12280050) was used for the SARS-CoV-2 viral RNA extraction according to the manufacturer's instructions, for which 200 µL of each NPS or saliva sample was used. For each batch of clinical samples to be tested, an extraction control (EC) was included (spike 20 µL of EC from the QuantiVirus™ SARS-CoV-2 multiplex kit into 180 µL sterile RNase-free water). The clinical samples and spiked EC were processed and extracted on the MGI platform. The extraction output is RNA in 30-50 µL RNase-free water, 5.5 µL of which is used for the PCR reaction per test. The turnaround time from sample extraction to PCR final report is around 4 hrs (Figure 1B). Precautions were taken while handling extracted RNA samples to avoid RNA degradation. Extracted RNA samples were stored at -80°C if not immediately used for RT-PCR.

Multiplex primer and probe design

Target gene sequences in the SARS-CoV-2 genome, the N gene, E gene and ORF1ab gene were identified and selected for test development. The gene sequences were retrieved from GenBank and GISAID databases for primer and probe designs to ensure

coverage of all SARS-CoV-2 strains. Multiple alignments of the collected sequences were performed using CLC Main Workbench 20.0.4., and conserved regions in each target gene were identified using BioEditor 7.2.5. prior to primer and probe designs. Primers and probes were designed to target the most conserved regions of each of the target genes of the viral genome, using Primer3plus software and following general rules of real-time PCR design. All primers were designed with a melting temperature (T_m) of approximately 60°C and the probes were designed with a T_m of about 65°C. The amplicon sizes were kept as short as possible within the range of 70 bp to 150 bp for each primer pair to achieve better amplification efficiency and detection sensitivity. All primers and probes were synthesized by Integrated DNA Technologies, Inc. (IDT, Coralville, IA, USA) and LGC Biosearch Technologies (Novato, CA, USA), respectively.

Real-time reverse-transcription PCR (rRT-PCR)

The total volume of one RT-PCR reaction for all targets is 10 µL, including 5.5 µL of RNA, 2.0 µL of 5x primer and probe mixture (final concentration of 0.2 µM and 0.1 µM, respectively), and 2.5 µL of 4x TaqPath™ 1-Step RT-qPCR Master Mix (Catalog number A28526, Thermo Fisher, Waltham, MA) or 4x Inhibitor-Tolerant RT-qPCR mix (MDX016-50, Meridian Bioscience, Tennessee). Thermal cycling was performed at 25°C for 2 min for UNG incubation and 53°C for 10 min for reverse transcription, followed by 95°C for 2 min and then 45 cycles of 95°C for 3 sec, and 60°C for 30 sec. QuantStudio™ 5 Real-Time PCR System (Thermo Fisher, USA), Applied Biosystems™ 7500 Fast Dx Real-Time PCR Instrument (Thermo Fisher, USA), BioRad CFX384 (Bio-Rad, USA) and Roche LightCycler 480 II (Roche, USA) were used for rRT-PCR amplification and detection.

Microorganism Panel for cross-reactivity

MERS- coronavirus, SARS-CoV coronavirus samples were ordered from IDT. NATtrol Respiratory Validation Panel was ordered from ZeptoMetrix (cat# NATRVP-3, Buffalo, NY). RNA/DNA were extracted from high titer stocks of the potentially cross-reacting microorganisms.

Statistical data analysis

Average cycle threshold (Ct), standard deviation (SD) and coefficient of variation (CV) were calculated using Microsoft Office Excel 365 software (Microsoft, Redmond, WA). Clinical sensitivity, clinical specificity, Positive Predictive Value (PPV) and Negative Predictive value (NPV) at two-sided 95% confidence interval (CI) were analyzed using MedCalc software Version 19.3.1. ROC curve was plotted by R package pROC. NP and saliva pair analysis was conducted by Wilcoxon signed rank test.

Results

Validation of QuantiVirus™ SARS-CoV-2 Multiplex Test kit

Analytical sensitivity

We validated the QuantiVirus™ SARS-CoV-2 Multiplex kit on four qPCR instruments from different vendors, using contrived saliva samples. The overall analytical sensitivity (lower limit of detection or LOD) is around 100-200 copies/mL.

The validation data established that the LOD of the assay is 200 copies/mL on ABI 7500 Fast Dx (Table 1a), 100 copies/mL on Bio-Rad CFX384 (Table 1b), 200

copies/mL on Roche LightCycler 480 II (Table 1c), and 200 copies/mL on the Thermo Fisher QuantStudio 5 (Table 1d).

Cross-reactivity (assay specificity)

We tested the cross-reactivity as part of the assay development. MERS-coronavirus and SARS-CoV coronavirus samples were ordered from IDT and NATtrol Respiratory Verification Panel from ZeptoMetrix (cat#NATRVP-3). RNA/DNA were extracted from high titer stocks of the potentially cross-reacting microorganisms (estimated 1.0E+05 units/mL), RNA/DNA were extracted from 100 µL microorganisms' stocks using the Thermo Fisher viral RNA extraction kit (PureLink™ Viral RNA/DNA Mini Kit) or Qiagen QIAamp DNA Mini Kit. Extracted RNA/DNA were eluted to 100 µL with sterile RNase-free water. 5.5 µL of the purified RNA/DNA samples was used for each reaction and tested using the QuantiVirus™ SARS-CoV-2 multiplex Test Kit. The cross-reactivity testing results are summarized in Table 2.

The cross-reactivity tests were run in triplicate, and all test controls passed (Positive controls Ct<25, No target control Ct >45, Extraction control has RP Ct ~28). The tested organisms were all negative for the targeted N, E and ORF1ab genes of SARS-CoV-2, indicating there is no cross-reactivity between SARS-CoV-2 primers & probes and any of the comparison organisms tested. The cross reactivity with common Human coronaviruses and MERS-coronavirus was also tested, and there was no cross reactivity at 10⁵ PFU/mL.

Assay sensitivity verification

We spiked non-infectious viral particles (SeraCare AccuPlex SARS-CoV-2 Reference Material Kit, Cat # 0505-0126) into healthy donor saliva which were confirmed by SARS-CoV-2 qPCR test to be negative, and tested each using three different qPCR instruments, ABI QuantStudio 5, ABI 7500 Fast Dx and BioRad CFX 384.

Clinical evaluation of the QuantiVirus™ SARS-CoV-2 Multiplex Test was conducted with saliva specimens including 40 contrived positive and 30 negative samples. Saliva samples collected from healthy donors were mixed with the lysis buffer at 1:1 ratio before spiking in non-infectious viral particles (SeraCare AccuPlex SARS-CoV-2 Reference Material Kit) (Table 3).

20 contrived positive saliva samples were created with the addition of non-infectious viral particles templates at 1x estimated LOD (1x200 copies/mL), 10 saliva samples were spiked at 1.5xLoD (300 copies/mL), and another 10 saliva samples were spiked at 2.5xLoD (500 copies/mL). Viral RNA was extracted from spiked samples and tested with the QuantiVirus™ SARS-CoV-2 multiplex test kit. The results showed that all 40 spiked saliva samples tested positive and all 30 control saliva samples tested negative on all three PCR instruments (Tables 3a, b and c) with PPA being 100% (95% CI: 0.76-0.99) and NPA of 100% (95% CI: 0.91-1.00).

Clinical evaluation on NPS samples

Using the QuantiVirus™ SARS-CoV-2 Multiplex Test, we tested clinical NPS samples including 85 positive samples and 90 negative samples which previously had been tested on Abbott m2000 molecular system using Abbott Real-Time SARS-CoV-2 testing kits (Table 4). The data shows that the clinical sensitivity of QuantiVirus™ SARS-CoV-2

multiplex test is 98.8% (95% CI: 92.7% -99.9%) and specificity is 100% (95% CI: 94.9%-100%). Its PPV is 100% (95% CI: 94.6%-100%) and NPV is 98.9% (95% CI: 93.1%-99.9%). ROC curve shows its AUC = ~0.988 for this sensitivity and specificity (Figure 2).

Clinical evaluation of paired NPS and saliva samples

We tested and evaluated the concordance between paired NPS and saliva samples collected from patients by QuantiVirus™ SARS-CoV-2 multiplex tests. Among the 20 pairs of nasopharyngeal swabs (NP) and saliva samples, the test results were the same for 16 pairs (16/20, 80% concordance rate), including 5 positive pairs and 11 negative pairs. There were four samples for which the results were discordant (Table 5). Of these four pairs, one pair was NPS positive and saliva negative, whereas the other three pairs were NPS negative and saliva positive. Nevertheless, we compared NPS and saliva specimens by Wilcoxon matched pair signed rank test. The two samples types show 80% concordance with no significant differences ($p=0.13$, Figure 3a), and its RP were similar between two types of specimens ($p=0.06$, Figure 3b).

Comparison of QuantiVirus™ SARS-CoV-2 multiplex kit with FDA EUA approved Abbott Realtime SARS-CoV-2 kit

We tested 24 saliva samples of recovering COVID-19 patients with the QuantiVirus™ SARS-CoV-2 multiplex kit in comparison with the Abbott m2000 SARS-CoV-2 PCR kit in parallel (Table 6). Data showed a concordance of the assays of about 88%. There were three samples detected by QuantiVirus™ SARS-CoV-2 multiplex kit, but not

detectable with the Abbott kit (patients #8, 11 and 12), consistent with the reported higher sensitivity of QuantiVirus™ PCR assay.²²

Population screening using saliva samples

We tested 389 total saliva specimens from the general population of asymptomatic people in Los Angeles and the San Francisco Bay Area. The screened population was represented by African Americans, White, Asian, and Latinx, with ages ranging from 18 to 80 (average 41) years old. From May 8 to Aug 26, 2020, 301 saliva samples were tested, and 5 samples were tested positive for SARS-CoV-2 by the QuantiVirus™ SARS-CoV-2 multiplex PCR test. The 5 positives corresponded to 4 males of ages 19, 51, 52 and 54, and 1 female of age 34. Overall detection rate was 1.66% (Table 7). In another recent testing run of 88 saliva samples, 2 samples were positive and 86 were negative, with an overall positive detection rate of 2.27%. Overall, we had screened 389 people from the general population and found that 7 people were positive for SARS-CoV-2 with a detection rate of 1.8%, consistent with the reported average positive test rate from the same periods in the two metropolitan regions.

Evaluation of pooling saliva samples for SARS-CoV-2 screening

To test the feasibility of pooling saliva specimens for screening asymptomatic patients, we pooled healthy donor saliva (negative) and patient saliva (positive) and tested a total of 77 pooled samples (1 patient sample mixed with 5 healthy saliva samples) and 54 pooled health samples (mixed 6 health samples) (Table 8). Of the 77 pooled saliva samples, 73 were tested positive (average Ct of three genes: O gene Ct~29.8; E gene 30.9 and N gene Ct ~31,0) and 4 was negative. The average IC RP Ct was 21.9 for all

131 pooled samples. Positive Predictive Value (PPV) is 100% (95% CI: 93.8%-100%). Negative Predictive Value (NPV) is 93.1% (95% CI: 82.5-97.8%). Additionally, we tested a total of 49 pooled saliva samples, created by mixing 1 patient sample with 11 healthy samples. Of the 49 pooled samples, 44 were detected positive (O gene, E gene and N gene average Ct 31.8, 32.1 and 31.9) and 5 was negative. Its IC RP average Ct was 22.3 for all 49 pooled saliva samples and additional 20 pooled healthy saliva samples. PPV is 100% (95% CI: 89.9%-100%) and NPV is 80.0% (95% CI: 58.7%-92.4%), respectively.

Discussion

We have developed and validated a multiplex rRT-PCR assay for SARS-CoV-2 detection with clinical sensitivity being 98.8% (95% CI: 92.7%-99.9%) and specificity of 100% (95% CI: 94.9%-100%). Its PPV is 100% (95% CI: 94.6%-100%) and NPV is 98.9% (95% CI: 93.1%-99.9%). The ROC curve shows an AUC of ~0.988. The detection of three viral target genes in one PCR tube enables a high throughput test using RT- qPCR. For these validated PCR platforms, 381 patient samples can be tested in each run (plus 3 controls). We have developed and integrated MGISP-960 High-throughput Automated Sample Preparation System which can extract 192 samples (2x96) in about 80 min. For CLIA labs with two MGI-960 machines, 380 samples can be tested with results available within 4 hrs. (Figure 1b)

We spiked SARS-CoV-2 viral particles into healthy donor saliva and confirmed that the analytical sensitivity (LOD) of the QuantiVirus™ multiplex RT-qPCR test is ~100 copies/mL for Bio-Rad CFX 384 and ~200 copies/mL for ABI QS5, ABI 7500Dx and

Roche LC 480. The multiplex RT-qPCR test can simultaneously detect three viral gene targets, which can minimize false negative results as chances of simultaneous mutations in all three target genes in the viral genome are highly unlikely. On the other hand, this also confirms that human saliva samples do not inhibit the RT-qPCR reaction possibly due to the fact that inhibitor-tolerant RT-PCR master mix was used in the QuantiVirus™ SARS-CoV-2 test kit.

Leung et al ⁶ analyzed 95 patient-matched paired samples from 62 patients including 29 confirmed patients with COVID-19 and 33 COVID-19 negative patients. The concordance rate was 78.9% (75/95 samples) between NP and saliva. Vogels et al ¹⁹ reported a positive agreement of 83.8% (31/37 positive samples) for nasopharyngeal swabs and saliva when using TaqPath COVID-19 combo kit. Our data showed 80% concordance and no significant differences between NP and saliva, which is consistent with Leung's & Vogels's reports. Interestingly, for patient #4, the viral RNA was detected in the NPS sample by both Abbott test and DiaCarta test, but viral RNA was not detected in the saliva by either test. For patient #6, viral RNA was not detected in the NPS sample by either test, whereas viral RNA was detected in the saliva by both tests. This observation suggests that sample collection variables such as the time of collection and NPS sample quality do matter in SARS-CoV-2 testing.

The 20 paired NPS-saliva samples were collected from recovering patients being evaluated prior to their release from self-quarantine. Consequently, their viral loads were much lower (100-1000 copies/mL), compared to the viral loads expected for the initial diagnostic testing. For patients with active SARS-CoV-2 infection (viral loads typically are

above 10,000 copies/mL), there should be no problem detecting the virus in adequately collected saliva samples.

Landry et al ²⁰ described that most of saliva samples from sick patients were thick, stringy, and difficult to pipet. Since we used the QuantiVirus™ SARS-CoV-2 saliva sample collection kit which has VTM solution in the collection tube, the saliva was diluted 50% and therefore much easier to process. Matic et al ²¹ used PBS at a 1:2 dilution that also helped resolve highly viscous saliva samples; however, manual dilution after collection may be associated with pipetting errors and cross contamination.

The QuantiVirus™ SARS-CoV-2 multiplex test results were 87.5% in concordance with FDA EUA approved Abbott RealTime SARS-CoV-2 results for saliva samples, with a higher detection rate overall. In fact, this observation is consistent with recently reported test sensitivity among various SARS-CoV-2 molecular tests. FDA published its SARS-CoV-2 Reference Panel Comparative Data on its website on Sept 15th, 2020 ²². It reported that QuantiVirus™ SARS-CoV-2 multiplex Kit has LOD of 600 NDU/mL whereas Abbott Realtime SARS-CoV-2 assay has LOD of 5400 NDU/mL. Accordingly, the reason for the observation that SARS-CoV-2 viral RNA was detected in three patient samples by the QuantiVirus™ SARS-CoV-2 multiplex test but not by Abbott Realtime SARS-CoV-2 assay was likely due to the higher sensitivity of the QuantiVirus™ SARS-CoV-2 multiplex assay. It also demonstrated that saliva specimens represent a viable specimen type that can be easily applied for COVID-19 testing when using more sensitive tests.

A total of 389 saliva specimens from the general population were tested and demonstrated the feasibility of using saliva for large scale population screening. Saliva is a non-invasive and easily collectable specimen for COVID-19 screening. Given the

drawbacks of nasopharyngeal and oropharyngeal swab sample collection, saliva sampling could be applied as an acceptable alternative ²³.

With saliva pooling strategy, we have demonstrated that 6-samples pooling (1 patient mixed with 5 healthy saliva samples) has 94.8% sensitivity (95% CI: 86.5-98.3%) and 100% specificity (95% CI:91.7-100%), As noted, of the 77 pooled saliva samples, 4 pooling samples were tested negative. In fact, for these 4 pooled samples, the individual patient samples used for the pooling had Ct of 34.4, 34.8, 35.7 and 37.5 for ORF1ab gene, respectively, consistent with low viral loads (less than 100-200 copies/mL) (see Table 1a-d). Therefore, in order to detect weakly positive patient in pooled samples, a RT-PCR test with LOD at 100-200 copies/mL or better is required. If pooling testing is considered, each clinical laboratory should establish laboratory-specific pooling protocol based on the LOD of SARS-CoV-2 molecular test.

In summary, we have demonstrated that saliva specimens can be reliably used for SARS-CoV-2 detection, and saliva-based large-scale population screening for COVID-19 with or without pooling is feasible.

Acknowledgements

The authors thank Dr. Ramanathan Vairavan and Eric Chu for reviewing and editing this manuscript, and Christopher Teixeira, Fady Etnas, Enas Eltarazy and Eric Abbott for their technical contributions.

References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 382 (2020) 727-733
2. World Health Organization (WHO). Coronavirus. Geneva: WHO; 2020 [Accessed 21 Jan 2020]. Available from: <https://www.who.int/health-topics/coronavirus>
3. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *N Engl J Med*. 382 (2020) 1199-1207
4. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 395(2020) 507-514.
5. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *Lancet*. 395 (2020) 514-523.
6. Leung EC, Chow VC, Lee MK and Lai RW. Deep throat saliva as an alternative diagnostic specimen type for the detection of SARS-CoV-2. *J Med Virol*. (2020)1–4
<https://doi.org/10.1002/jmv.26258>
7. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 581 (2020) 465–469
8. He X, Lau EH, Wu P, Deng X, Wang J, Hao X et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nat Med* 26 (2020) 672–675.
9. Nagura-Ikeda M, Imai K, Tabata S, Miyoshi K, Murahara N, Mizuno T et al. Clinical evaluation of self-collected saliva by RT-qPCR, direct RT-qPCR, RT-LAMP, and a rapid antigen test to diagnose COVID-19. *J Clin Microbiol*. 58 (2020) e01438-20

10. Kinloch N, Ritchie G, Brumme CJ, Dong W, Dong W, Lawson T et al. Suboptimal biological sampling as a probable cause of false-negative COVID-19 diagnostic test results. *J Infect Dis* 222(2020) 899–902
11. Wyllie A, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P. et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* (2020) doi: <https://doi.org/10.1101/2020.04.16.20067835>
12. Hanson KE, Barker AP, Hillyard D.R, Gilmore N, Barrett JW, Orlandi RR et al. Self-collected anterior nasal and saliva specimens versus healthcare worker-collected nasopharyngeal swabs for the molecular detection of SARS-CoV-2. *J. Clin. Microbiol.* (2020). Doi:10.1128/JCM.012824-20
13. Centre for Health Protection. Severe respiratory disease associated with a novel infectious agent—letters to doctors. (2020). Accessed: February 5, 2020: <https://www.chp.gov.hk/en/miniweb/letters/100063.html>.
14. FDA EUA, Individual EUAs for Molecular Diagnostic Tests for SARS-CoV-2 <https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-diagnostics-euas#umbrella-molecular>
15. Sri Santosh T, Parmar R, Anand H, Srikanth K, Saritha M. A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19. *Cureus* 12 (2020) e7708. DOI 10.7759/cureus.7708
16. To KK, Tsang OT, Yip CC, Chan KH, Wu TC, Chan JM. et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clin. Infect. Dis.* 71 (2020) 841-843. doi:10.1093/cid/ciaa149.

17. Chen L, Zhao J, Peng J, Li X, Deng X, Geng Z. et al. Detection of 2019-nCoV in Saliva and Characterization of Oral Symptoms in COVID-19 Patients. (2020) <https://ssrn.com/abstract=3557140>
18. Xu R, Cui B, Duan X, Zhang P, Zhou X and Yuan Q. 2020. Saliva: potential diagnostic value and transmission of 2019-nCoV. International Journal of Oral Science 12 (2020):11 <https://doi.org/10.1038/s41368-020-0080-z>
19. Vogels C, Watkins A, Harden C, Brackney D, Shafer J, Wang J. et al. SalivaDirect: Simple and sensitive molecular diagnostic test for SARS-COV-2 surveillance. MedRxiv (2020) <https://doi.org/10.1101/2020.08.03.20167791>
20. Landy M, Criscuolo J and Peaper D. Challenges in use of saliva for detection of SARS-COV-2 RNA in symptomatic outpatients. J. Clinical Virology 130 (2020) 104567.
21. Matic N, Lawson T, Ritchie G, Stefanovic A, Leung V, Champagne S. et al Automated molecular testing of saliva for SARS-COV-2 detection. MedRxiv (2020) <https://doi.org/10.1101/2020.08.11.20170613>
22. FDA SARS-CoV-2 Reference Panel Comparative Data <https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-reference-panel-comparative-data?from=singlemessage&isappinstalled=0>
23. Fakheran O, Dehghannejad M and Khademi A. Saliva as a diagnostic specimen for detection of SARS-CoV-2 in suspected patients: a scoping review. Infectious Diseases of Poverty 9 (2020) 100-107 <https://doi.org/10.1186/s40249-020-00728-w>

(B)

Figure 1. (A) SARS-CoV-2 genome structure and assay target genes. (B) a high throughput workflow for SARS-COV-2 detection from sample collection to result availability within about 4 hrs.

Figure 2. ROC curve of the QuantiVirus™ SARS-CoV-2 multiplex test for detecting SARS-CoV-2 using NPS samples, with specificity data on X axis and sensitivity on Y axis. AUC (Area Under Curve) was calculated as 0.988. This figure was plotted by R package pROC.

Figure 3. Clinical evaluation of paired nasopharyngeal and saliva samples.

Cycle threshold (Ct) values for target gene and RP gene of NPS and saliva specimens were compared by Wilcoxon matched pairs signed rank test.

Cycle threshold (Ct) values for viral E gene, N gene, O gene (ORF1ab), and human RNase P gene (RP) for NP and saliva specimens. A) E, N, and O Ct values for paired NP and saliva samples. Pairs are connected by a line. The Ct was set to 42 for samples in which signal was not detected. Ct values of E, N, and O were comparable between the two types of samples by Wilcoxon signed rank test. NPS and saliva concordance is about 80% with no significant differences ($p=0.13$). B) RP Ct values for NP and saliva specimens were similar between the two types of samples by Wilcoxon signed rank test.

Table 1a. Summary of twenty replicates for analytical sensitivity confirmation on the ABI 7500 Dx

Target	RNA (copy/mL)	Total	Avg Ct	SD	CV	Positive	Negative	Call Rate
ORF1ab gene	100 copies/mL	20	34.28	1.05	3.08%	20	0	100%
N gene	100 copies/mL	20	35.73	1.12	3.13%	20	0	100%
E gene	200 copies/mL	20	34.24	0.98	2.87%	20	0	100%

Table 1b. Summary of twenty replicates for analytical sensitivity confirmation on the BioRad CFX 384

Target	RNA (copy/mL)	Total	Avg Ct	SD	CV	Positive	Negative	Call Rate
ORF1ab gene	100 copies/mL	20	33.76	0.97	2.87%	20	0	100%
N gene	100 copies/mL	20	35.97	1.02	2.85%	20	0	100%
E gene	100 copies/mL	20	37.87	0.58	1.52%	20	0	100%

Table 1c. Summary of twenty replicates for analytical sensitivity confirmation on the Roche LC 480

Target	RNA (copy/mL)	Total	Avg Ct	SD	CV	Positive	Negative	Call Rate
ORF1ab gene	100 copies/mL	20	32.85	0.57	1.7%	20	0	100%
N gene	200 copies/mL	20	35.04	0.58	1.7%	20	0	100%
E gene	100 copies/mL	20	36.13	0.59	1.6%	20	0	100%

Table 1d. Summary of twenty replicates for analytical sensitivity confirmation on the ABI QS5

Target	RNA (copy/mL)	Total	Avg Ct	SD	CV	Positive	Negative	Call Rate
ORF1ab gene	200 copies/mL	20	34.09	0.66	1.92%	20	0	100%
N gene	200 copies/mL	20	35.11	1.81	5.14%	20	0	100%
E gene	200 copies/mL	20	34.99	1.68	4.82%	20	0	100%

Table 2. Summary of cross-reactivity evaluation of the QuantiVirus™ SARS CoV-2 Test

Organisms	N gene (CY5)			Orf1ab gene (FAM)			E gene (TexReD)			RP gene (HEX)		
	Mean	STD	CI	Mean	STD	CI	Mean	STD	CI	Mean	STD	CI
Coronavirus 229E	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	39.76	3.72	9.59
Coronavirus HKU-1	45.00	0.00	0.00	45.00	0.00	0.00	41.47	5.00	12.90	41.86	4.44	11.45
Coronavirus NL63	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Coronavirus OC43	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	41.21	2.88	7.44
Influenza A H1N1pdm	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Influenza AH1	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Influenza AH3	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Influenza B	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Parinfluenza 1	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Parinfluenza 2	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Parinfluenza 3	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Parinfluenza 4	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
Adenovirus3	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	33.64	0.35	0.89
Metapneumovirus	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	44.16	1.19	3.07
Rhinovirus	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	41.69	3.65	9.41
RSV A	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
B.pertussis	45.00	0.00	0.00	41.64	4.75	12.26	45.00	0.00	0.00	45.00	0.00	0.00
C.pneumoniae	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	42.04	4.19	10.81
M.pneumoniae	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
H.influenzae	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
P.aeruginosa	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
S.pneumoniae	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
S.pyogenes	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
SARS	45.00	0.00	0.00	45.00	0.00	0.00	42.19	3.97	10.25	45.00	0.00	0.00
MERS	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
RP	38.68	4.48	11.57	45.00	0.00	0.00	45.00	0.00	0.00	23.93	0.09	0.23
NTC	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00	45.00	0.00	0.00
PC_kit	19.74	0.06	0.15	18.30	0.03	0.09	19.33	0.03	0.07	45.00	0.00	0.00
PC_4gblock	22.14	0.10	0.25	21.12	0.07	0.17	23.12	0.08	0.20	24.59	0.10	0.25

*RP-internal control; NTC-no target control; PC-kit –kit positive control; PC_4gblock-gblock positive control.

Table 3a. Evaluation of contrived clinical sample with viral particles (Bio-Rad CFX 384)

Specimen Type	Viral RNA Concentration (copies/mL)	SARS-CoV-2			Performance	95% CI
		Positive	Negative	Total		
Viral RNA + saliva	200 copies/mL (1xLoD)	20	0	20	100%	76.4-99.1%
	300 copies/mL (1.5x LoD)	10	0	10	100%	72.3-100%
	500 copies/mL (2.5x LoD)	10	0	10	100%	72.3-100%
H2O + saliva	0 copy/mL	0	30	30	100%	90.6-100%

*Note: saliva specimens include 40 positive and 30 negative samples

Table 3b. Evaluation of contrived clinical sample with viral particles (ABI QuantStudio 5)

Specimen Type	Viral RNA Concentration (copies/mL)	SARS-CoV-2			Performance	95% CI
		Positive	Negative	Total		
Viral RNA +saliva	200 copies/mL (1xLoD)	20	0	20	100%	76.4-99.1%
	300 copies/mL (1.5xLoD)	10	0	10	100%	72.3-100%
	500 copies/mL (2.5xLoD)	10	0	10	100%	72.3-100%
H2O + saliva	0 copy/mL	0	30	30	100%	90.6-100%

Table 3c. Evaluation of contrived clinical sample with viral particles (ABI 7500 Fast Dx)

Specimen Type	Viral RNA Concentration (copies/mL)	SARS-CoV-2			Performance	95% CI
		Positive	Negative	Total		
Viral RNA +saliva	200 copies/mL (1xLoD)	20	0	20	100%	76.4-100%
	300 copies/mL (1.5xLoD)	10	0	10	100%	72.3-100%
	500 copies/mL (2.5xLoD)	10	0	10	100%	72.3-100%
H2O + saliva	0 copy/mL	0	30	30	100%	90.6-100%

Table 4. Clinical Sample Evaluation with QuantiVirus™ SARS-CoV-2 Multiplex Test

Patients samples	N	SARS-CoV-2		Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
		Detected	Not Detected				
Positive	85	84	1	98.8% (0.927 - 0.999)	100 % (0.949-1.00)	100 % (0.946-1.00)	98.9 % (0.931-0.999)
Negative	90	0	90				

* ABIQS5 qPCR instrument was used for this test.

Table 5. Paired NPS and Saliva Tested by QuantiVirus™ SARS-CoV-2 Multiplex Test

Sample Test	Diacarta PCR 4plex NP				Diacarta PCR 4plex Saliva			
	Accession #	Test Status	Ct of E, N, ORF	RP	Accession #	Test Status	Ct of E, N, ORF	RP
patient 1	NPS1	Not Detected		24.5	Saliva 1	Not Detected		21.6
patient 2	NPS2	Not Detected		23.8	Saliva 2	Not Detected		22.9
patient 3	NPS3	Not Detected		23.8	Saliva 3	Not Detected		22.1
patient 4	NPS4	Detected	E38.7	25.9	Saliva 4	Not Detected		21.6
patient 5	NPS5	Detected	E38.2; O44.6	26.6	Saliva 5	Detected	E32, N31.7; O29.9	20.7
patient 6	NPS6	Not Detected		24.7	Saliva 6	Not Detected		19.7
patient 7	NPS7	Not Detected		22.1	Saliva 7	Not Detected		23.3
patient 8	NPS8	Detected	O 38.1	19.7	Saliva 8	Detected	N24.4	21.8
patient 9	NPS9	Not Detected		23.5	Saliva 9	Not Detected		22.3
patient 10	NPS10	Not detected		29.7	Saliva 10	Detected	E32.8, N33.9; O31.5	23.9
patient 11	NPS11	Not detected		28.5	Saliva 11	Detected	E35.7; N38.5; O33.9	24.2
patient 12	NPS12	Not detected		28.4	Saliva 12	Not detected		24.5
patient 13	NPS13	Detected	E38.4; N 36.9; ORF 33.9	26.1	Saliva 13	Detected	E36.1; N37.0; O34.0	26.1
patient 14	NPS14	Detected	E35.4; N35.4; ORF 36.2	29.0	Saliva 14	Detected	E35.6; N35.1; O34.2	23.6
patient 15	NPS15	Not detected		25.5	Saliva 15	Not detected		25.19
patient 16	NPS16	Not Detected		19.0	Saliva 16	Not Detected		22.68
patient 17	NPS17	Not Detected		20.2	Saliva 17	Not Detected		21.43
patient 18	NPS18	Not Detected		20.7	Saliva 18	Not Detected		22.07
patient 19	NPS19	Detected	O27.64	19.3	Saliva 19	Detected	15.01	17.5
patient 20	NPS20	Not Detected		17.7	Saliva 20	Detected	O23.9	20.4
Concordance Rate (%)	80.0%							

Table 6. Comparison of Abbott m2000 SARS-CoV-2 PCR test and DiaCarta QuantiVirus™

SARS-CoV-2 multiplex PCR test

Method Comparison	Abbott m2000 Real-time SARS-CoV-2		Diacarta QuantiVirus SARS-CoV-2 multiplex				
	Accession #	Detection & qPCR Ct	Detection	ROX(E-Gene)	Cy5(N-Gene)	FAM(ORF 1ab gene)	VIC(RP Gene)
Patient 1	Saliva 1	Not Detected	Not Detected	Undetermined	Undetermined	Undetermined	21.6
Patient 2	Saliva 2	Not Detected	Not Detected	Undetermined	undetermined	Undetermined	22.9
Patient 3	Saliva 3	Not Detected	Not Detected	Undetermined	undetermined	Undetermined	22.1
Patient 4	Saliva 4	Not Detected	Not Detected	Undetermined	undetermined	Undetermined	21.6
Patient 5	Saliva 5	Detected (Ct 18.21)	Detected	32.1	31.7	30.0	20.7
Patient 6	Saliva 6	Detected (Ct 31.00)	Detected	Undetermined	37.8	Undetermined	23.7
Patient 7	Saliva 7	Not Detected	Not Detected	Undetermined	Undetermined	Undetermined	19.7
Patient 8	Saliva 8	Not Detected	Detected	37.4	37.3	42.4	23.3
Patient 9	Saliva 9	Detected (Ct 23.89)	Detected	Undetermined	24.4	undetermined	21.8
Patient 10	Saliva 10	Not Detected	Not Detected	Undetermined	undetermined	Undetermined	22.3
Patient 11	Saliva 11	not detected	Detected	32.8	33.9	31.5	23.9
Patient 12	Saliva 12	not detected	Detected	35.7	38.5	33.9	24.2
Patient 13	Saliva 13	Not Detected	Not detected	Undetermined	43.5	Undetermined	24.5
Patient 14	Saliva 14	Detected (Ct 20.77)	Detected	36.1	37.0	34.0	26.1
Patient 15	Saliva 15	Detected	Detected	35.6	35.1	34.2	23.6
Patient 16	Saliva 16	Not Detected	Not detected	Undetermined	37.7	Undetermined	23.6
Patient 17	Saliva 17	Not Detected	Not detected	Undetermined	Undetermined	41.2	32.7
Patient 18	Saliva 18	Not Detected	Not detected	Undetermined	Undetermined	Undetermined	24.9
Patient 19	Saliva 19	Not Detected	Not detected	Undetermined	Undetermined	33.5	29.1
Patient 20	Saliva 20	Detected (Ct. 21.40)	Detected	Undetermined	39.4	36.8	26.6
Patient 21	Saliva 21	Not Detected	Not detected	Undetermined	Undetermined	Undetermined	25.1
Patient 22	Saliva 22	Not Detected	Not detected	Undetermined	43.5	Undetermined	23.6
Patient 23	Saliva 23	Not Detected	Not detected	Undetermined	Undetermined	Undetermined	29.1
Patient 24	Saliva 24	Not Detected	Not detected	Undetermined	Undetermined	Undetermined	25.2

Table 7. Summary of saliva-based COVID-19 screening using QuantiVirus™ SARS-CoV-2 multiplex PCR test

Date	Total (N)	Positive	Negative	Detection Rate (%)
May 8-Aug 26	301	5	296	1.66%
28-Aug	88	2	86	2.27%
Total	389	7	382	1.80%

Table 8. Saliva sample pooling for SARS-CoV-2 detection by QuantiVirus™ SARS-COV-2 multiplex PCR test

Saliva Sample Pooling	Sample Test (N)	Positive	Negative	Screen Sample(N)	Sensitivity	Specificity	PPV (%)	NPV (%)
1 patient + 5 health pooling	77	73	4	462	94.8% (95%CI: 0.865-0.983)	100% (95% CI: 0.917-1.00)	100% (95% CI: 0.938-1.00)	93.1% (95%CI: 0.825-0.978)
6 health pooling	54	0	54	324				
1 patient + 11 health pooling	49	44	5	588	89.8% (95% CI: 0.769-0.962)	100% (95% CI:0.799-1.00)	100% (95% CI: 0.899-1.00)	80.0% (95% CI: 0.587-0.924)
12 health pooling	20	0	20	240				